Bluejay Diagnostics (BJDX) Net Margin (2022)
Bluejay Diagnostics (BJDX) reported Net Margin of 853.67% for Q2 2022.
Bluejay Diagnostics (BJDX) Net Margin (2022) Analysis & Trends
Bluejay Diagnostics (BJDX) has 1 years of Net Margin data on file, last reported at 853.67% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 12.84% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 16.74% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 3.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 8.01% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Bluejay Diagnostics | 2,754.24 | 2,754.24 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -853.67% |